Go Pro
→ Elon’s AI Phone is coming (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agrify Corporation stock logo
AGFY
Agrify
$23.01
-2.0%		$22.04
$13.22
▼
$48.84
$46.09M9.9631,892 shs4,988 shs
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$7.30
$7.30
$2.00
▼
$16.10
$11.72M1.185,025 shsN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
$2.12
-1.9%		$2.17
$1.79
▼
$5.18
$45.44M0.44148,773 shs80,176 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$4.39
-1.3%		$4.78
$3.53
▼
$9.12
$44.28M1.1157,290 shs31,616 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agrify Corporation stock logo
AGFY
Agrify
0.00%+1.05%-2.06%-18.89%-39.19%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00%0.00%0.00%0.00%-41.69%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-1.85%+0.47%-1.40%-10.74%-31.61%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-1.35%-1.57%-22.57%+14.03%-49.66%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agrify Corporation stock logo
AGFY
Agrify
$23.01
-2.0%		$22.04
$13.22
▼
$48.84
$46.09M9.9631,892 shs4,988 shs
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$7.30
$7.30
$2.00
▼
$16.10
$11.72M1.185,025 shsN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
$2.12
-1.9%		$2.17
$1.79
▼
$5.18
$45.44M0.44148,773 shs80,176 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$4.39
-1.3%		$4.78
$3.53
▼
$9.12
$44.28M1.1157,290 shs31,616 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agrify Corporation stock logo
AGFY
Agrify
0.00%+1.05%-2.06%-18.89%-39.19%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00%0.00%0.00%0.00%-41.69%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-1.85%+0.47%-1.40%-10.74%-31.61%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-1.35%-1.57%-22.57%+14.03%-49.66%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agrify Corporation stock logo
AGFY
Agrify
0.00
N/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00
N/AN/AN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
2.00
Hold$6.00183.02% Upside
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
2.33
Hold$33.00651.71% Upside

Current Analyst Ratings Breakdown

Latest FNCH, AGFY, SCYX, and GRCE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$24.00 ➝ $33.00
8/3/2026
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
7/31/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Brookline Capital Markets logo
Brookline Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/24/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/10/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/26/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 9/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agrify Corporation stock logo
AGFY
Agrify
$12.26M3.76N/AN/A$10.47 per share2.20
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/A$14.25 per shareN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/AN/AN/AN/A$3.99 per shareN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$20.60M2.12N/AN/A$9.07 per share0.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agrify Corporation stock logo
AGFY
Agrify
-$41.75M-$22.65N/AN/AN/A-424.11%-185.90%-72.67%N/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-$74.75M-$8.82N/AN/AN/AN/A-69.14%-26.92%N/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$7.79M-$1.18N/AN/AN/AN/A-36.11%-34.39%11/12/2026 (Estimated)
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$8.61M-$2.09N/AN/AN/A-41.79%-44.15%-32.61%11/4/2026 (Estimated)

Latest FNCH, AGFY, SCYX, and GRCE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q1 2027
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$0.1293-$0.91-$0.7807-$0.91$0.40 millionN/A
8/10/2026Q2 2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.5067$0.63+$1.1367$0.63$0.08 million$0.24 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Agrify Corporation stock logo
AGFY
Agrify
N/AN/AN/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/AN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agrify Corporation stock logo
AGFY
Agrify
1.43
2.64
2.52
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/A
3.87
3.87
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/A
11.47
11.47
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/A
9.65
9.65

Institutional Ownership

CompanyInstitutional Ownership
Agrify Corporation stock logo
AGFY
Agrify
5.98%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
21.77%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
6.08%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%

Insider Ownership

CompanyInsider Ownership
Agrify Corporation stock logo
AGFY
Agrify
2.16%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
44.90%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
10.84%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
4.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agrify Corporation stock logo
AGFY
Agrify
1402.00 million1.96 millionNot Optionable
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
1901.61 million885,000No Data
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
521.04 million18.76 millionN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
299.95 million9.54 millionOptionable

Recent News About These Companies

SCYNEXIS (NASDAQ:SCYX) Shares Pass Above 50-Day Moving Average - Time to Sell?
September 23 at 4:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31041579
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
September 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scynexis-appoints-seasoned-industry-veteran-steven-k-burke-m-d-to-its-board-of-directors-1036563490
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D.
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366246/0/en/scynexis-appoints-seasoned-industry-veteran-steven-k-burke-m-d-to-its-board-of-directors.html
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
September 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/15/3362033/0/en/scynexis-appoints-todd-minga-m-d-as-senior-vice-president-research-development.html
SCYNEXIS Names Sanjay Subramanian as CFO
September 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scynexis-names-sanjay-subramanian-cfo-125711695.html
Scynexis Names Sanjay Subramanian CFO
September 10, 2026  |  rttnews.comhttps://www.rttnews.com/3690011/scynexis-names-sanjay-subramanian-cfo.aspx
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
September 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359427/0/en/scynexis-announces-appointment-of-sanjay-subramanian-as-chief-financial-officer.html
SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Above Fifty Day Moving Average - Here's What Happened
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-scynexis-nasdaq-scyx-stock-price-passes-above-fifty-day-moving-average-heres-what-happened-2026-09-09/
SCYNEXIS to Participate in Upcoming Investor Conferences
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354140/0/en/scynexis-to-participate-in-upcoming-investor-conferences.html
SCYNEXIS (NASDAQ:SCYX) Shares Pass Below 200 Day Moving Average - Should You Sell?
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-scynexis-nasdaq-scyx-shares-pass-below-200-day-moving-average-should-you-sell-2026-09-01/
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
August 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/25/3351035/0/en/scynexis-announces-inducement-award-under-nasdaq-listing-rule-5635-c-4.html
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 10, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/08/10/10427949.htm
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3319628/0/en/scynexis-initiates-phase-1-study-of-scy-770-a-novel-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd.html
SCYNEXIS Shareholders Approve Governance and Equity Plan Changes
June 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/scynexis-shareholders-approve-governance-and-equity-plan-changes?utm_source=marketbeat.com&utm_medium=referral
SCYNEXIS Inc.
June 24, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/Stock/SCYX/financials
SCYNEXIS Announces One-for-Eight Reverse Stock Split
May 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/22/3300360/0/en/scynexis-announces-one-for-eight-reverse-stock-split.html
SCYNEXIS (SCYX) price target increased by 20.73% to 4.28
May 14, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/scynexis-scyx-price-target-increased-by-2073-to-428/ar-AA23cbkM
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/11/3292371/0/en/scynexis-reports-first-quarter-2026-financial-results-and-provides-corporate-update.html
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3289542/0/en/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635-c-4.html
SCYNEXIS Raises $40 Million in Strategic Private Placement
April 19, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SCYX/pressreleases/1093176/scynexis-raises-40-million-in-strategic-private-placement/
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript
March 31, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4887596-scynexis-inc-scyx-discusses-transformative-asset-acquisition-and-strategic-shift-toward-adpkd

New MarketBeat Followers Over Time

Media Sentiment Over Time

Agrify stock logo

Agrify NASDAQ:AGFY

$23.01 -0.46 (-1.96%)
As of 09/23/2026

Agrify Corporation offers hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. It offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. The company also provides associated services comprising consulting, engineering, and construction. In addition, the company offers hydrocarbon, alcohol, solventless, post-processing, and lab equipment, as well as provides indoor farming solutions. In addition, it offers equipment and services in a contract and purchase order. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Troy, Michigan.

Finch Therapeutics Group stock logo

Finch Therapeutics Group NASDAQ:FNCH

$7.30 0.00 (0.00%)
As of 09/24/2026

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Grace Therapeutics stock logo

Grace Therapeutics NASDAQ:GRCE

$2.12 -0.04 (-1.85%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$2.17 +0.05 (+2.36%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

SCYNEXIS stock logo

SCYNEXIS NASDAQ:SCYX

$4.39 -0.06 (-1.35%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$4.39 0.00 (0.00%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas